Your browser doesn't support javascript.
loading
[Consider (es)ketamine for treatment-resistant depression]. / Overweeg (es)ketamine bij therapieresistente depressie.
van Verseveld, Mike; Stuiver, Sven; Vos, Cornelis F; Ruhé, Henricus G; van Waarde, Jeroen A; Kramers, C Kees.
Afiliação
  • van Verseveld M; Rijnstate, afd. Psychiatrie, Arnhem.
  • Stuiver S; Contact: Mike van Verseveld (mike.vanverseveld@outlook.com).
  • Vos CF; Rijnstate, afd. Psychiatrie, Arnhem.
  • Ruhé HG; Radboudumc, Nijmegen. Afd. Psychiatrie.
  • van Waarde JA; Radboudumc, Nijmegen. Afd. Psychiatrie.
  • Kramers CK; Rijnstate, afd. Psychiatrie, Arnhem.
Ned Tijdschr Geneeskd ; 1672023 06 22.
Article em Nl | MEDLINE | ID: mdl-37493307
Major depressive disorder has a high prevalence globally. Although pharmacotherapy and psychotherapy are effective for most patients, about one third is treatment resistant. Ketamine, known as an anesthetic, is a new treatment option that can be effective in patients with treatment-resistant depression. (es)ketamine works relatively fast. However, the long-term effects are still relatively unknown. In the Netherlands, S-Ketamine is currently administered in various forms, of which only the nasal spray is registered for treatment-resistant depression. Currently, many studies have been conducted on the use of (es)ketamine. In this article we describe the latest state of affairs regarding its effectiveness and safety.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior / Ketamina Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: Nl Ano de publicação: 2023 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior / Ketamina Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: Nl Ano de publicação: 2023 Tipo de documento: Article